During and After Myeloma CAR T-Cell Therapy | What to Expect
https://vimeo.com/1164531913 Dr. Ciara Freeman, a myeloma specialist from Moffitt Cancer Center, helps patients and care partners understand the day-to-day reality of CAR T-cell therapy. Dr. Freeman provides an overview of…
Preparing for Myeloma CAR-T Cell Therapy | What to Expect
https://vimeo.com/1164531947 Dr. Ciara Freeman provides an overview of what patients and care partners can expect before CAR T-cell therapy—from deciding if CAR T is right for you to getting physically…
How Has Myeloma CAR T-Cell Therapy Changed in Recent Years?
https://vimeo.com/1164531973 Dr. Ciara Freeman, a myeloma specialist from Moffitt Cancer Center, explains CAR T-cell therapy in simple terms, sharing how this treatment is changing the future for people with myeloma….
Research Updates From ASH | Myeloma CAR T-Cell Therapy
https://vimeo.com/1164531982 Myeloma expert and researcher Dr. Ciara Freeman shares key CAR T-cell therapy advances presented at the 2025 American Society of Hematology (ASH) meeting. Dr. Freeman also provides an explanation…
复发后的骨髓瘤：新研究对患者的意义
https://vimeo.com/1160266766 德克萨斯大学MD安德森癌症中心的Krina K. Patel医学博士讨论了MAJESTIC-3临床试验中令人鼓舞的新数据，该研究针对首次复发后的多发性骨髓瘤患者，评估了两种免疫疗法联合使用的效果。她解释了这种治疗方法的工作原理、为何研究结果如此令人振奋，以及为何支持性治疗对于安全管理治疗至关重要。Patel医生还分享了实用见解，帮助患者理解这一治疗选择在其整体治疗路径中的潜在定位，在带来希望的同时，强调经过深思熟虑的个体化决策的重要性。 See More from [ACT]IVATED Multiple Myeloma Related Resources What Are Myeloma Risk Factors for Veterans and First Responders? How AI Is Shaping the Future of CAR…
Mieloma Después de la Recaída: Lo Que la Nueva Investigación Significa para los Pacientes
https://vimeo.com/1160265495 La Dra. Krina K. Patel del Centro de Cáncer MD Anderson de la Universidad de Texas analiza datos alentadores del ensayo clínico MAJESTIC-3, que estudió una combinación de dos…
Myeloma After Relapse: What New Research Means for Patients
Dr. Krina K. Patel of The University of MD Anderson Cancer Center discusses encouraging new data from the MAJESTIC-3 clinical trial, which studied a combination of two immunotherapies for people…
¿Por Qué Importa la Representación en los Ensayos Clínicos de Cáncer de Próstata?
https://vimeo.com/1160173617 ¿Por qué importa la inclusión en los ensayos clínicos de cáncer de próstata, y cómo pueden los pacientes ayudar a impulsar el cambio? En este segmento de [ACT]IVATED, la…
Why Does Representation in Prostate Cancer Clinical Trials Matter?
https://vimeo.com/1159829275 Why does inclusion in prostate cancer clinical trials matter, and how can patients help drive change? In this [ACT]IVATED segment, Dr. Leanne Woods-Burnham of Morehouse School of Medicine explains…
¿Esto aplica para mí? Cómo acceder a nuevas opciones para el cáncer de próstata
https://vimeo.com/1160173600 Cuando se anuncian nuevas terapias para el cáncer de próstata, los pacientes a menudo preguntan: “¿Esto aplicará para mí?” En este programa [ACT]IVATED, la Dra. Leanne Woods-Burnham de la…
Will This Apply to Me? How to Access New Prostate Cancer Options
https://vimeo.com/1159829399 When new prostate cancer therapies are announced, patients often ask, “Will this apply to me?” In this [ACT]IVATED program, Dr. Leanne Woods-Burnham of Morehouse School of Medicine shares simple,…
ELEVATE | From Research to Recovery: CAR T-Cell Therapy for Myeloma Patients
https://vimeo.com/1159341084 What if myeloma returns after CAR T-cell therapy? Dr. Doris Hansen reviews additional options for patients, including repeat CAR-T treatments, bispecific and trispecific immunotherapies, and other emerging drugs in…